We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pacira (PCRX) Down 3.6% Since Last Earnings Report: Can It Rebound?
Read MoreHide Full Article
A month has gone by since the last earnings report for Pacira (PCRX - Free Report) . Shares have lost about 3.6% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Pacira due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Pacira's Q4 Earnings Surpass Estimates, Revenues Miss
Pacira reported fourth-quarter 2020 earnings of 87 cents per share, beating the Zacks Consensus Estimate of 82 cents and also increasing from the year-ago earnings of 56 cents.
Total revenues increased 7% to $131 million from the year-earlier figure of $122.4 million in the fourth quarter of 2020. However, the top line missed the Zacks Consensus Estimate of $132 million.
Quarter in Detail
Pacira’s top line mainly comprises of product revenues, other product sales and royalty revenues.
Exparel net product sales were $125.3 million, up 7% from $116.9 million generated in the year-ago quarter. Sale of the drug also grew 10.2% on a sequential basis.
Notably, iovera system generated sales worth $2.4 million in the fourth quarter of 2020, reflecting a sequential decrease of 11.1%.
Royalty revenues came in at $1.2 million in the reported quarter, up 100% year over year.
Research and development (R&D) expenses (excluding stock-based compensation) fell approximately 22.9% to $14.1 million.
Selling, general and administrative (SG&A) expenses (excluding stock-based compensation) also decreased around 6.1% year over year to $44.7 million in the reported quarter.
2021 Outlook
Owing to the adverse effects of the COVID-19 pandemic negatively impacting the sale, Pacira is not providing the guidance for 2021.
How Have Estimates Been Moving Since Then?
It turns out, estimates review flatlined during the past month.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pacira (PCRX) Down 3.6% Since Last Earnings Report: Can It Rebound?
A month has gone by since the last earnings report for Pacira (PCRX - Free Report) . Shares have lost about 3.6% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Pacira due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Pacira's Q4 Earnings Surpass Estimates, Revenues Miss
Pacira reported fourth-quarter 2020 earnings of 87 cents per share, beating the Zacks Consensus Estimate of 82 cents and also increasing from the year-ago earnings of 56 cents.
Total revenues increased 7% to $131 million from the year-earlier figure of $122.4 million in the fourth quarter of 2020. However, the top line missed the Zacks Consensus Estimate of $132 million.
Quarter in Detail
Pacira’s top line mainly comprises of product revenues, other product sales and royalty revenues.
Exparel net product sales were $125.3 million, up 7% from $116.9 million generated in the year-ago quarter. Sale of the drug also grew 10.2% on a sequential basis.
Notably, iovera system generated sales worth $2.4 million in the fourth quarter of 2020, reflecting a sequential decrease of 11.1%.
Royalty revenues came in at $1.2 million in the reported quarter, up 100% year over year.
Research and development (R&D) expenses (excluding stock-based compensation) fell approximately 22.9% to $14.1 million.
Selling, general and administrative (SG&A) expenses (excluding stock-based compensation) also decreased around 6.1% year over year to $44.7 million in the reported quarter.
2021 Outlook
Owing to the adverse effects of the COVID-19 pandemic negatively impacting the sale, Pacira is not providing the guidance for 2021.
How Have Estimates Been Moving Since Then?
It turns out, estimates review flatlined during the past month.